StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mg
April 24, 2018 6:01 AM
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Eli Lilly (LLY) PT Maintained at $95 at Cowen on 1Q18 Report; 'Top & Bottom Line Beat... FY18 Guidance Raised'
April 24, 2018 11:50 AM
Incyte (INCY) PT Lowered to $83 at BofA/Merrill Lynch
April 24, 2018 9:17 AM
Incyte (INCY) Announces Expanded Clinical Collaboration with Immunovaccine Inc. to Evaluate Combination Immunotherapies in Advanced Recurrent Ovarian Cancer
April 24, 2018 7:12 AM
Incyte (INCY) PT Raised to $77 at RBC Capital; 'Base Case'
April 24, 2018 6:29 AM
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
April 23, 2018 8:11 PM
FDA Votes 10-5 to Back Incyte (INCY) and Lilly's (LLY) Baricitinib 2 mg, Votes 5-10 Against 4 mg
April 23, 2018 4:54 PM
Amid drug price worries, earnings to test U.S. pharma, biotech shares
April 23, 2018 4:49 PM
Incyte (INCY), Lilly (LLY) Low Dose Baricitinib Wins FDA Panel Vote on Safety; High Does Fails to Win Panel Vote on Safety - Bloomberg
April 23, 2018 4:41 PM
Incyte (INCY), Eli Lilly (LLY) Panel Going More Favorably Than Previously Suggested - RBC
April 23, 2018 12:43 PM
Eli Lilly & Co. (LLY) Reports Additional Top-Line Results from CYRAMZA Phase 3 RANGE Study
April 20, 2018 2:50 PM
